There were mortality reductions in subgroups of age 51–65 years (HR 0.46, 95% CI: 0.23–0.93), stage I–III (HR 0.48, 95% CI: 0.30–0.77), surgery (HR 0.48, 95% CI: 0.28–0.71), chemotherapy (HR 0.51, 95% CI: 0.33–0.79), pre-diagnosis ACE inhibitors users (HR 0.40, 95% CI: 0.22–0.74) and patients who had hypertension prior to the ovarian cancer diagnosis (HR 0.51, 95% CI: 0.31–0.85) (Table 5). The gene discussed is ACE; the disease is ovarian carcinoma.